Experimental combo targets Hard-to-Treat brain cancers
NCT ID NCT00268385
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-stage study tested the safety and best dose of vorinostat when given with the chemotherapy drug temozolomide in 83 adults with aggressive brain tumors called malignant gliomas. The goal was to see if adding vorinostat could make the tumor cells more sensitive to chemotherapy, potentially improving treatment. The study focused on finding the safest dose and monitoring side effects, not on curing the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT ANAPLASTIC ASTROCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
National Cancer Institute Neuro-Oncology Branch
Bethesda, Maryland, 20892, United States
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
-
UCSF Medical Center-Mount Zion
San Francisco, California, 94115, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a parasite drug fight childhood brain tumors?
- Can mapping the Blood-Brain barrier in brain tumors unlock new clues?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Brain cancer vaccine targets survivin protein to boost immune attack
- AI reads brain scans to predict tumor survival before surgery
- Can a drug make radiation work better against aggressive brain tumors?